SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

OS Therapies Inc
Date: May 28, 2025 · CIK: 0001795091 · Accession: 0000000000-25-005634

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287569

Date
May 28, 2025
Author
Division of
Form
UPLOAD
Company
OS Therapies Inc

Letter

Re: OS Therapies Incorporated Registration Statement on Form S-1 Filed May 23, 2025 File No. 333-287569 Dear Paul A. Romness:

May 28, 2025

Paul A. Romness President and Chief Executive Officer OS Therapies Incorporated 115 Pullman Crossing Road, Suite #103 Grasonville, MD 21638

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Dakota J. Forsyth, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 28, 2025

Paul A. Romness
President and Chief Executive Officer
OS Therapies Incorporated
115 Pullman Crossing Road, Suite #103
Grasonville, MD 21638

 Re: OS Therapies Incorporated
 Registration Statement on Form S-1
 Filed May 23, 2025
 File No. 333-287569
Dear Paul A. Romness:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Dakota J. Forsyth, Esq.
</TEXT>
</DOCUMENT>